59 Leukemia Clinical Trials in Philadelphia, PA (2026)

Q: Are there leukemia clinical trials in Philadelphia?

Yes, there are 59 leukemia clinical trials currently recruiting in Philadelphia, PA.

Q: How do I join a clinical trial in Philadelphia?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you.

Q: Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Leukemia Studies in Philadelphia

NCT07133074Recruiting

Allergy Delabeling in Antibiotic Stewardship - Intervention

The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy....

Philadelphia, PAPHASE43,800 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT06525064Recruiting

Health-E You Efficacy Trial for Male Adolescents

This study will involve evaluating Health-E You/Salud ìTu™, a web-based, pre-visit mobile app designed to support adolescent male youth and his clinicians in discussing sexual and reproductive health ...

Philadelphia, PANA2,752 participantsJohns Hopkins University

View Study Details

NCT06529575Recruiting

Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children

This multisite study seeks to understand whether and how pulse oximeter accuracy varies across children with different skin colors in real world clinical settings. Many factors can affect how well pul...

Philadelphia, PA650 participantsUniversity of Pennsylvania

View Study Details

NCT07458347Recruiting

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutatio...

Philadelphia, PAPHASE1545 participantsKestrel Therapeutics, Inc.

View Study Details

NCT07037758Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to...

Philadelphia, PAPHASE1380 participantsAmgen

View Study Details

NCT06043817Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cel...

Philadelphia, PAPHASE1345 participantsAntares Therapeutics, Inc

View Study Details

NCT04959175Recruiting

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherap...

Philadelphia, PAPHASE1320 participantsNational Cancer Institute (NCI)

View Study Details

NCT06788756Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with ...

Philadelphia, PAPHASE2312 participantsMoleculin Biotech, Inc.

View Study Details

NCT07174583Recruiting

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC....

Philadelphia, PAPHASE1262 participantsIDEAYA Biosciences

View Study Details

NCT04068597Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk M...

Philadelphia, PAPHASE1250 participantsCellCentric Ltd.

View Study Details

NCT07117136Recruiting

Blinatumomab Consolidation in Real World

This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap...

Philadelphia, PA200 participantsMedical College of Wisconsin

View Study Details

NCT06681220Recruiting

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Parti...

Philadelphia, PAPHASE1166 participantsVA Office of Research and Development

View Study Details

NCT04276870Recruiting

Orphan Indications for CD19 Redirected Autologous T Cells

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very h...

Philadelphia, PAPHASE2133 participantsStephan Grupp MD PhD

View Study Details

NCT07223021Recruiting

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblast...

Philadelphia, PAPHASE3130 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06514794Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a ther...

Philadelphia, PAPHASE2125 participantsWugen, Inc.

View Study Details

NCT07216105Recruiting

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without pacli...

Philadelphia, PAPHASE1119 participantsFate Therapeutics

View Study Details

NCT05480449Recruiting

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acu...

Philadelphia, PAPHASE1115 participantsStephan Grupp MD PhD

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

Philadelphia, PAPHASE1114 participantsIpsen

View Study Details

NCT06839456Recruiting

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threat...

Philadelphia, PAPHASE1100 participantsChildren's Hospital of Philadelphia

View Study Details

NCT05502523Recruiting

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in pa...

Philadelphia, PANA100 participantsThomas Jefferson University

View Study Details

NCT05909501Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in...

Philadelphia, PA100 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT02356653Recruiting

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant...

Philadelphia, PAEARLY_PHASE1100 participantsChildren's Hospital of Philadelphia

View Study Details

NCT06579469Recruiting

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in r...

Philadelphia, PA100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT05674175Recruiting

Co-administration of CART22-65s and huCART19 for B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL)....

Philadelphia, PAPHASE193 participantsStephan Grupp MD PhD

View Study Details

NCT06731907Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical rem...

Philadelphia, PAPHASE290 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05612789Recruiting

Improve Outcomes for Older Allogeneic Transplant Recipients

This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to deter...

Philadelphia, PANA72 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT06846606Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinica...

Philadelphia, PAPHASE169 participantsAuron Therapeutics, Inc.

View Study Details

NCT06794229Recruiting

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed b...

Philadelphia, PAPHASE269 participantsQian Qin

View Study Details

NCT07027514Recruiting

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with...

Philadelphia, PAPHASE160 participantsAnkyra Therapeutics, Inc

View Study Details

NCT06651970Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's...

Philadelphia, PAPHASE460 participantsAstraZeneca

View Study Details

NCT07057791Recruiting

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonesci...

Philadelphia, PAPHASE260 participantsPrECOG, LLC.

View Study Details

NCT04332367Recruiting

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in particip...

Philadelphia, PAPHASE259 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT05442216Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...

Philadelphia, PAPHASE253 participantsJoshua Zeidner

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Philadelphia, PAPHASE152 participantsCellectis S.A.

View Study Details

NCT03810196Recruiting

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T deple...

Philadelphia, PANA50 participantsChildren's Hospital of Philadelphia

View Study Details

NCT07012044Recruiting

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of impr...

Philadelphia, PAPHASE147 participantsNational Cancer Institute (NCI)

View Study Details

NCT04713657Recruiting

Beta-blocker Administration for Cardiomyocyte Division

Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the potential to pro...

Philadelphia, PAPHASE140 participantsWeill Medical College of Cornell University

View Study Details

NCT07276789Recruiting

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intrave...

Philadelphia, PAPHASE235 participantsIntegro Theranostics

View Study Details

NCT04925479Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib fro...

Philadelphia, PAPHASE134 participantsNovartis Pharmaceuticals

View Study Details

NCT06934382Recruiting

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy....

Philadelphia, PAPHASE133 participantsStephan Grupp MD PhD

View Study Details

NCT06222580Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relap...

Philadelphia, PAPHASE130 participantsUma Borate

View Study Details

NCT06173518Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients...

Philadelphia, PAPHASE130 participantsAutolus Limited

View Study Details

NCT06587165Recruiting

Quantifying New Heart Muscle Cells

Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after...

Philadelphia, PANA30 participantsWeill Medical College of Cornell University

View Study Details

NCT07592221Recruiting

Combined Functional Electrical and Transcranial Direct Current Stimulation for Foot Drop

This study aims to determine if combining the treatments of transcranial direct current stimulation (tDCS) and functional electrical stimulation (FES) will better help persons with stroke who have dif...

Philadelphia, PANA30 participantsSaint Joseph's University, Philadelphia

View Study Details

NCT07464951Recruiting

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. S...

Philadelphia, PAPHASE130 participantsStephan Grupp MD PhD

View Study Details

NCT04691817Recruiting

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer....

Philadelphia, PAPHASE128 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT04990102Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose ...

Philadelphia, PAPHASE124 participantsGeorgetown University

View Study Details

NCT06177067Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid...

Philadelphia, PAPHASE124 participantsSt. Jude Children's Research Hospital

View Study Details

NCT05627232Recruiting

Tazemetostat and Palbociclib With CPX-351for R/R AML

This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the combination of tazemetostat and CPX-351 (Part 1) and of pre-treatment with palbociclib followed...

Philadelphia, PAPHASE124 participantsThomas Jefferson University

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Philadelphia, PAPHASE120 participantsAdaptimmune

View Study Details

NCT03680677Recruiting

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic...

Philadelphia, PA20 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT06376162Recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or...

Philadelphia, PAPHASE120 participantsPedAL BCU, LLC

View Study Details

NCT05945849Recruiting

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells t...

Philadelphia, PAPHASE116 participantsUniversity of Pennsylvania

View Study Details

NCT06984562Recruiting

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims t...

Philadelphia, PANA16 participantsFox Chase Cancer Center

View Study Details

NCT07772895Recruiting

Pemefolacianine for IMI of Lung Cancer

The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of Pemefolacianine for Injection, a novel fluorescence imaging agent developed by Nanjing Nuoyuan M...

Philadelphia, PAPHASE112 participantsSunil Singhal

View Study Details

NCT05498792Recruiting

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab a...

Philadelphia, PAEARLY_PHASE112 participantsFox Chase Cancer Center

View Study Details

NCT03546829Recruiting

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete. The second phase is a single arm phase 1 safety study. Patients planned to undergo ...

Philadelphia, PAPHASE110 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT07116057Recruiting

MOv19-BBz CAR T Cells in FRa+ Cancers

This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This stud...

Philadelphia, PAPHASE110 participantsUniversity of Pennsylvania

View Study Details

NCT05452720Recruiting

MASA Valve Early Feasibility Study

The MASA Valve Early Feasibility Study (MVEFS) multi-site interventional clinical trial within the United States of America with each center following a common protocol.The objective of the trial is t...

Philadelphia, PANA10 participantsPECA Labs

View Study Details

About Leukemia Clinical Trials in Philadelphia

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 59 leukemia clinical trials recruiting participants in Philadelphia, PA. These studies are seeking a combined 12,590 participants. Research is being sponsored by Abramson Cancer Center at Penn Medicine, Johns Hopkins University, University of Pennsylvania and 37 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Philadelphia — FAQ

Are there leukemia clinical trials in Philadelphia?

Yes, there are 59 leukemia clinical trials currently recruiting in Philadelphia, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 59 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated October 16, 2026 from ClinicalTrials.gov